TP-110

WARNING: This product is for research use only, not for human or veterinary use.

Description:TP-110 is a new proteasome inhibitor, which shows potent growth inhibition in various tumor cell lines. Treatment with TP-110 for 24 h in vitro induced apoptosis in multiple myeloma cell line RPMI8226. TP-110 reduced the intrinsic inhibitor of apoptosis proteins (IAPs), cIAP-1 and XIAP, that suppress executioner caspases.

Price and Availability

TP-110is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 406717Name: TP-110CAS#: 688737-95-3Chemical Formula: C37H41N3O6Exact Mass: 623.29954Molecular Weight: 623.73794Elemental Analysis: C, 71.25; H, 6.63; N, 6.74; O, 15.39

Synonym:TP110; TP-110; TP 110; Tyropeptin A7.

IUPAC/Chemical Name:(2S)-2-((2S)-3-(4-methoxyphenyl)-N-(1-(4-methoxyphenyl)-3-oxopropan-2-yl)-2-(2-(naphthalen-1-yl)acetamido)propanamido)-3-methylbutanamide

SMILES Code:CC(C)[C@H](N(C(C=O)CC1=CC=C(OC)C=C1)C([C@@H](NC(CC2=C3C=CC=CC3=CC=C2)=O)CC4=CC=C(OC)C=C4)=O)C(N)=O

Technical Data

Additional Information

References

1: Iijima M, Momose I, Ikeda D. Increased ABCB1expression in TP-110-resistant RPMI-8226 cells. Biosci BiotechnolBiochem. 2010;74(9):1913-9. Epub 2010 Sep 7. PubMed PMID: 20834157.

2: Iijima M, Momose I, Ikeda D. TP-110, a new proteasome inhibitor,down-regulates IAPs in human multiple myeloma cells. Anticancer Res.2009 Apr;29(4):977-85. PubMed PMID: 19414335.

3: Watanabe T, Momose I, Abe M, Abe H, Sawa R, Umezawa Y, Ikeda D,Takahashi Y, Akamatsu Y. Synthesis of boronic acid derivatives oftyropeptin: proteasome inhibitors. Bioorg Med Chem Lett. 2009 Apr15;19(8):2343-5. doi: 10.1016/j.bmcl.2009.02.117. Epub 2009 Mar 4.PubMed PMID: 19307118.

4: Zanzonico P, Dauer L, St Germain J. Operational radiation safety forPET-CT, SPECT-CT, and cyclotron facilities. Health Phys. 2008Nov;95(5):554-70. doi: 10.1097/01.HP.0000327651.15794.f7. PubMed PMID:18849690.

5: Momose I, Iijima M, Kawada M, Ikeda D. A new proteasome inhibitor,TP-110, induces apoptosis in human prostate cancer PC-3 cells. BiosciBiotechnol Biochem. 2007 Apr;71(4):1036-43. Epub 2007 Apr 7. PubMedPMID: 17420589.

6: Momose I, Umezawa Y, Hirosawa S, Iijima M, Iinuma H, Ikeda D.Synthesis and activity of tyropeptin A derivatives as potent andselective inhibitors of mammalian 20S proteasome. Biosci BiotechnolBiochem. 2005 Sep;69(9):1733-42. PubMed PMID: 16195592.

7: Momose I, Umezawa Y, Hirosawa S, Iinuma H, Ikeda D. Structure-baseddesign of derivatives of tyropeptin A as the potent and selectiveinhibitors of mammalian 20S proteasome. Bioorg Med Chem Lett. 2005 Apr1;15(7):1867-71. PubMed PMID: 15780623.

8: Spach MS, Heidlage JF, Darken ER, Hofer E, Raines KH, Starmer CF.Cellular Vmax reflects both membrane properties and the load presentedby adjoining cells. Am J Physiol. 1992 Dec;263(6 Pt 2):H1855-63. PubMedPMID: 1481909.

9: Dowden SB, Cossins L, Glazebrook J, Ramsden M, Strike P. DNA-damageinducible genes on the I group plasmid TP 110. Biochimie. 1982Aug-Sep;64(8-9):681-5. PubMed PMID: 6291638.